Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Tempest Therapeutics stock

Learn how to easily invest in Tempest Therapeutics stock.

Tempest Therapeutics is a biotechnology business based in the US. Tempest Therapeutics shares (TPST) are listed on the NASDAQ and all prices are listed in US Dollars. Tempest Therapeutics employs 17 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Tempest Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – TPST. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Tempest Therapeutics stock price (NASDAQ: TPST)

Use our graph to track the performance of TPST stocks over time.

Tempest Therapeutics shares at a glance

Information last updated 2023-01-28.
Latest market close$2.04
52-week range$1.06 - $4.55
50-day moving average $1.57
200-day moving average $2.19
Wall St. target price$17.67
PE ratio 0.2364
Dividend yield $0 (0%)
Earnings per share (TTM) $8.63

Buy Tempest Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Tempest Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tempest Therapeutics price performance over time

Historical closes compared with the close of $2.04 from 2023-01-27

1 week (2023-01-23) 2.00%
1 month (2022-12-30) 77.39%
3 months (2022-10-28) 4.62%
6 months (2022-07-29) 0.49%
1 year (2022-01-28) -44.86%
2 years (2021-01-29) 3.55%
3 years (2020-01-30) 8.46
5 years (2018-01-30) 87.16%

Is Tempest Therapeutics stock undervalued or overvalued?

Valuing Tempest Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tempest Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Tempest Therapeutics's P/E ratio

Tempest Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Tempest Therapeutics shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Tempest Therapeutics financials

Gross profit TTM $0
Return on assets TTM -29.87%
Return on equity TTM -97.81%
Profit margin 0%
Book value $2.55
Market capitalisation $21.5 million

TTM: trailing 12 months

Tempest Therapeutics share dividends

We're not expecting Tempest Therapeutics to pay a dividend over the next 12 months.

Have Tempest Therapeutics's shares ever split?

Tempest Therapeutics's shares were split on a 1:15 basis on 27 June 2021. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tempest Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Tempest Therapeutics shares which in turn could have impacted Tempest Therapeutics's share price.

Tempest Therapeutics overview

Tempest Therapeutics Inc. , a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Frequently asked questions

What percentage of Tempest Therapeutics is owned by insiders or institutions?
Currently 3.248% of Tempest Therapeutics shares are held by insiders and 71.251% by institutions.
How many people work for Tempest Therapeutics?
Latest data suggests 17 work at Tempest Therapeutics.
When does the fiscal year end for Tempest Therapeutics?
Tempest Therapeutics's fiscal year ends in December.
Where is Tempest Therapeutics based?
Tempest Therapeutics's address is: 7000 Shoreline Court, South San Francisco, CA, United States, 94080
What is Tempest Therapeutics's ISIN number?
Tempest Therapeutics's international securities identification number is: US87978U1088

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site